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Abstract
Background: Methylated CpG dinucleotides in promoters are associated with the loss of gene expression in
recombinant Chinese hamster ovary (CHO) cells during large-scale commercial manufacturing. We evaluated a
promoter devoid of CpG dinucleotides, CpGfree, in parallel with a similar CpG containing promoter, CpGrich, for
their ability to maintain the expression of recombinant enhanced green fluorescent protein (EGFP) after 8 weeks
of culturing.
Results: While the promoters gave similar transient expression levels, CpGfree clones had significantly higher
average stable expression possibly due to increased resistance to early silencing during integration into the
chromosome. A greater proportion of cells in clones generated using the CpGfree promoter were still expressing
detectable levels of EGFP after 8 weeks but the relative expression levels measured at week 8 to those measured at
week 0 did not improve compared to clones generated using the CpGrich promoter. Chromatin immunoprecipitation
assays indicated that the repression of the CpGfree promoter was likely linked to histone deacetylation and
methylation. Use of histone deacetylase inhibitors also managed to recover some of the lost expression.
Conclusion: Using a promoter without CpG dinucleotides could mitigate the early gene silencing but did not
improve longer-term expression stability as silencing due to histone modifications could still take place. The
results presented here would aid in promoter selection and design for improved protein production in CHO and
other mammalian cells.
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Background
Recombinant therapeutic proteins such as monoclonal
antibodies are currently used to treat various cancers
and autoimmune diseases. Chinese hamster ovary (CHO)
cells transfected with plasmid vectors carrying the required
gene are used to produce some of these recombinant prod-
ucts [1, 2]. Loss of recombinant gene expression in trans-
fected CHO cells during long-term culture is commonly
reported and is a major concern during production [3–6].
Any significant loss of productivity during the production
process can affect both product yield and quality [7]. It is
also preferred that cell lines are able to maintain recombin-
ant protein expression without the need to supplement any
selection reagent as these reagents are toxic and costly. Ex-
pression levels of the protein are expected to remain com-
parable to the start of culturing after the entire scale up and
production process, retaining at least 70 % of initial levels
for the clone to be considered stable [8].
One reason for the drop in expression is the gradual
loss of gene copies during long-term culture resulting in
decreased transcripts and thus the recombinant protein
level [9–11]. This loss of gene copies had been linked to
the inherent genetic instability of the recombinant CHO
cell lines [6]. There are also reports of recombinant
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CHO cell lines losing protein expression levels without
losing gene copies when the transcripts decrease due to
transcriptional silencing [3]. The high number of gene
copies integrated into the chromosome of high produ-
cing cell lines can result in repeat-induced gene silencing
[12]. Transcriptional silencing is also linked to methyl-
ated cytosine on the CpG dinucleotides of promoters in
recombinant protein producing CHO cells [4, 13–15].
CpGs are interesting, small DNA moieties which can be
easily interspersed within DNA sequences to exert sig-
nificant regulatory effect on gene expression [16]. CpG
is methylated by DNA methyltransferases (DNMT) and
the process silences genes by directly inhibiting tran-
scription activation through disrupting the binding of
transcription factors [17–19]. Methylated CpGs can
also interact and recruit proteins that repress gene ex-
pression. Proteins with methyl-CpG binding domains
(MBD) like MeCP2 can recruit either co-repressors or
chromatin modifying enzymes like histone deacetylases
(HDAC) [15, 20]. As maintaining transgene expression
level is important to many applications, several solu-
tions to reduce the effects of gene silencing due to CpG
methylation and improve expression stability have been
proposed.
A possible solution is to include epigenetic regulatory
DNA elements which are able to modify the chromatin
structure and aid in maintaining an open chromatin
structure for gene expression [21]. Use of DNA regulatory
elements like the locus control regions (LCR), matrix at-
tachment regions (MAR) [22–24], insulators [25], CpG is-
land elements (IE) [26] and ubiquitous chromatin opening
elements (UCOE) [27, 28] have been discussed in reviews
[21, 29]. Another possible solution is to supplement the
culture media with DNMT inhibitors to delay or reverse
DNA methylation to maintain expression [13, 30]. This
can be hard to implement as the chemicals could be toxic
and the transient effects are reversed once the chemical is
removed. We could also maintain expression by keeping
the selection pressure used to identify positive trans-
fectants. Gene expression can also be maintained by
supplementing the selection drug throughout culture
period. Studies have shown that under selective condi-
tions, integrated CpG rich reporters were not susceptible
to methylation [31]. Care has to be taken when using
media additives as some additives could complicate down-
stream processes and add costs to production [32]. An-
other solution could be to prevent CpG methylation from
taking place by using promoters free of CpG. CpG free
promoters and plasmids have been commonly adopted in
gene therapy to reduce inflammation and methylation
related loss of expression [33]. We had also previously
observed that promoters with lower CpG counts exhib-
ited greater expression stability [23]. It is still unclear
how CpG free promoters would perform at improving
long-term recombinant gene expression stability in
transfected CHO cells.
In this study, we compared two promoters which com-
prised of the same enhancers and intron regions, and
core promoters from a similar source with the main dif-
ference being that one promoter is free of CpG dinucle-
otides. The promoters were used to drive the expression
of a recombinant enhanced green fluorescent protein
gene (EGFP) in CHO cells. The promoters had similar
transient expression levels but the CpG free promoter
had significantly higher stable expression levels. Stability
of the EGFP expression was evaluated after 8 weeks of
passaging without any selection pressure. Interestingly,
CpGfree promoter increased the proportion of cells ex-
pressing detectable levels of EGFP in clones after 8 weeks
but not the relative expression levels compared to the
CpGrich promoter. Subsequent chromatin immunopre-
cipitation (ChIP) analysis revealed similar gene repres-
sing histone modifications in unstable clones from both
the CpGfree and CpGrich promoters.
Methods
Vector construction
The promoters used in this study combined the mouse
cytomegalovirus (CMV) enhancer, the human elongation
factor 1 alpha core promoter and a synthetic intron at
the 5′ untranslated region (UTR). CpG carrying versions
of the promoter was cloned from the pCpGrich-mcs
vector (InvivoGen, San Diego, CA) and the CpG free
version was cloned from pCpGfree-mcs (InvivoGen).
The promoters were labelled as CpGrich and CpGfree
respectively and the sequences are listed in Fig. 1a. The
cloned promoters were used to replace the human CMV
promoter of a bicistronic vector for expressing EGFP used
in a previous study to generate the vectors CpGrich and
CpGfree [23] (Fig. 1b). An attenuated internal ribosome
entry site (IRESatt) and mutant neomycin phosphotrans-
ferase (mNPT) was used to increase the stringency of se-
lection for high producing cell lines [34–36].
Cell culture and transfection
CHO K1 cells (American Type Culture Collection,
Manassas, VA) were cultured in tissue culture plates using
Dulbecco’s modified Eagle’s medium (DMEM) +Gluta-
MaxTM (Life Technologies) supplemented with 10 % fetal
bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO). Cells
were passaged every 3 to 4 days by diluting cells to 2 × 105
cells/mL. Cell density and viability were measured using
the trypan blue exclusion method on a Vi-cell XR cell
viability analyzer (Beckman Coulter, CA).
Three separate transfections were performed using
each promoter using the Nucleofector I system from
Lonza (Cologne, Germany). 5 × 106 cells were transfected
with 5 μg of linearized plasmids in each transfection. The
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transfected cells were transferred to 6-well tissue culture
plates containing DMEM supplemented with 800 μg/mL
of G418 (Sigma-Aldrich) for selection 24 h after transfec-
tion. Fluorescence-activated cell sorting (FACS) analysis
was also performed using FACS Calibur (Becton Dickinson,
Franklin Lakes, NJ) to determine the transient expression
obtained using each promoter. Upon recovery of the stably
transfected pools, at least nine clones were randomly se-
lected from each stable pool by limiting dilution for a total
of 30 clones to be carried forward for stability tracking.
Stability tracking for stably transfected clones
Clones were subsequently cultured in 6-well tissue cul-
ture plates in the absence of G418 for 8 weeks. Mean
fluorescent intensity (MFI) for each clone before (week
0) and after (week 8) stability testing were measured
with a FACS Calibur (Becton Dickinson). Banked cells of
week 0 clones were thawed and EGFP expression quanti-
fied in parallel to ensure differences were not due to
drifts in the system’s sensors. EGFP expression retained
for each clone was calculated as the ratio of MFI of the
clone measured at the end of stability testing to the in-
tensity at the start of stability testing. Detailed protocols
for stability testing performed had been previously re-
ported [26]. Cells pellets were also collected at the start
and end of stability testing after centrifuging at 100 × g
for subsequent molecular analysis.
Determining gene copy and mRNA levels
Genomic DNA and total RNA were isolated from 5 × 106
cells using the Gentra Puregene Cell Kit (Qiagen, Hilden,
Germany) and the RNAqueous-4PCR kit (Ambion, Austin,
TX), respectively. The extracted RNA was used to generate
first-strand cDNA using ImProm-II Reverse Transcription
System (Promega, Madison, WI). Relative EGFP gene copy
numbers and mRNA levels were determined by using
real-time quantitative PCR as described previously [3].
β-actin and eukaryotic translation elongation factor-1
alpha-1 (EF1α1) served as the internal controls to
normalize the variation in input amount and quality of
DNA and mRNA respectively. Primer pairs used are as
follows: EGFP-forward (5′-CAAGCAGAAGAACGGCAT
CAA-3′) and EGFP-reverse (5′- GGACTGGGTGCTCA
GGTAGTG-3′), β-actin-forward (5′ AGCTGAGAGGGAA
ATTGTGCG-3′) and β-actin-reverse (5′- GCAACGGAA
CCGCTCATT-3′), EF1α1-forward (5′- TGGAAGATGGC
CCTAAATTC-3′) and EF1α1-reverse (5′- AACGACCCA
GTGGAGGATAG-3′).
ChIP for methylated DNA and chromatin modifications
ChIP assays were carried out using EZ ChIP kit (Millipore)
according to a modified process based on the manufac-
turer’s protocol. DNA fragments sized at between 200 and
1000 bp were obtained by sonication using a Microson
Ultrasonic Cell Disruptor (Misonix, Farmingdale, NY).
The antibodies used for IP were anti-5-methylcytosine
(anti-5-mC), anti-histone H3 acetyl-lysine 9 (anti-H3K9Ac),
anti-histone H3 trimethyl-lysine 9 (anti-H3K9Me3) and
anti-heterochromatin protein 1 (anti-HP1) (all from
Abcam, Cambridge, MA). Antibodies were added to the
sheared chromatin individually and incubated at 4 °C
overnight. The DNA/protein/antibody complex was then
pulled down by protein G agarose and the DNA in the
complex was purified using QIAquick PCR purification kit
(Qiagen). Real-time quantitative PCR was performed to
determine the relative amount of DNA that was immuno-
precipitated by each antibody in week 0 and week 8 sam-
ples. DNA enriched using anti-5-mC and anti-HP1
antibodies were quantified using primer pairs specific to
the promoters and DNA enriched using anti-H3K9Me3
and anti-H3K9Ac used primers specific to the EGFP gene.
The primer pairs used to amplify the CpGrich promoter,




5′-TTTACCCAAGCCCCACCTTC-3′) and EGFP (5′-
TACCAGCAGAACACCCCCAT -3′ and 5′- ACCATG
TGATCGCGCTTCTC -3′).
DNA methyltransferase and histone deacetylase inhibitor
treatment
Selected stable and unstable clones generated using both
promoters were seeded into 24-well plates at cell density
of 3 × 105 cells/mL and cultured for 24 h in selection
free DMEM. Media was changed to fresh DMEM con-
taining either 4 μM 5-Aza-2′-deoxycitidine (5-Aza-dC,
Sigma-Aldrich), a DNMT inhibitor, or 2 mM sodium
butyrate (NaBu, Sigma-Aldrich), a HDAC inhibitor, or
without inhibitors as a control. Cells were then further
cultured in the DMEM supplemented with inhibitors for
24 h before being harvested for FACS analysis to obtain
the MFI of the clones after treatment.
(See figure on previous page.)
Fig. 1 Promoter sequences and schematic representation of the vector used in the study. a Sequence of the CpGrich (top strand) and CpGfree
(bottom strand) promoters used in the study. Both promoters were cloned from vectors from InvivoGen. The promoters have 90 % similarity
and alignment was done online using nucleotide BLAST at http://blast.ncbi.nlm.nih.gov/Blast.cgi. b Structure of the expression cassette used
to express an enhanced green fluorescence protein (EGFP) and a mutant neomycin phosphotransferase selection marker with amino acid
substitution D261G (mNPT)
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Results
Generating clones and testing EGFP expression level and
stability
Transient expression using the two promoters, CpGrich
and CpGfree, were first compared. EGFP expression using
CpGfree was around 10 % higher than CpGrich but the
difference was not significant after normalizing for trans-
fection efficiency (Fig. 2). After confirming similarity in
the promoter strengths, we generated three stably trans-
fected pools separately for each promoter. The CpGfree
pools recovered (reached 80 % confluence) one passage
faster than the CpGrich pools. Heterogeneous pools were
not suitable for stability testing in our study as any loss of
recombinant protein expression in pools could be due to
clones with low expression level outgrowing the rest of
the population instead of molecular reasons like DNA
methylation. Upon recovery, we randomly selected at
least nine clones from each pool to obtain a total of 30
stably transfected clonal cell lines for each promoter.
We checked that the entire population of each clone
was expressing EGFP at the start of stability testing,
week 0. EGFP expression was higher for the CpGfree
clones with an average MFI of 530 compared to 336 for
the CpGrich clones (Fig. 3a). CpGfree stable pools also
had higher expression levels than CpGrich (data not
shown). The highest and lowest EGFP expressing clones
were similar for both promoters at MFI of around 900 and
150. These MFI readings were recorded as the EGFP
expression at week 0 for the clones. These two sets of
clones were subsequently passaged for 8 weeks without
any selection reagent before EGFP expression was mea-
sured again.
Expression stability was measured using two values,
the percentage of cells within the clonal population still
expressing EGFP levels above that of non-transfected
CHO K1 cells and the retention of EGFP expression
levels compared to week 0 after 8 weeks of culture. The
CpGrich clones had 83.9 % of the population retaining
EGFP population on average (Fig. 3b). 21 out of the 30
clones still had more than 90 % of the population ex-
pressing detectable levels of EGFP and the worst per-
forming clone had only 11.1 % of the population with
EGFP expression. CpGfree clones performed better,
averaging 94.6 % of the cells staying positive for EGFP
expression after 8 weeks. The worst performing clone
still had 60 % of the population expressing the recom-
binant protein.
The EGFP expression retained was determined as a ra-
tio of the expression level at week 8 to the level at week
0. There was no significant difference between the two
promoters for their ability to maintain gene expression
over the 8 weeks. The CpGrich clones retained an average
of 55 % of EGFP expression while the CpGfree clones per-
formed slightly better at 62 % (Fig. 3c). 13 of the 30
CpGrich clones still had expression above 70 % of their
initial expression and 14 of the 30 clones using CpGfree
achieving the same result. Our results indicated that using
CpGfree might be beneficial during the drug selection
process but does not provide any significant improve-
ments to long-term expression stability. Due to a higher
initial expression level, the final recombinant protein levels
were still higher despite no improvements to stability.
Quantitative PCR and ChiP assays were subsequently per-
formed to understand if the loss of expression was due to
Fig. 2 Comparing transient EGFP expression level obtained using the CpGrich and CpGfree promoters. Cells were transfected and EGFP
expression levels measured using a flow cytometer after 24 h. Each bar and standard deviation represents the results obtained from duplicate
experiments of three separately transfected pools. Results were normalized for transfection efficiency for each sample before normalizing to
CpGrich expression level
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changes in gene copies or other gene silencing related
molecular mechanisms.
Gene copy and mRNA levels of the clones before and
after stability testing
To understand why the CpGfree promoter did not have
a greater effect on improving stability, nine clones exhibit-
ing a range of retained expression were chosen for both
CpGrich and CpGfree promoters for gene copy and
mRNA level analysis. The clones ranged from retaining
only 1 % EGFP expression to those which maintained the
same expression level after the eight weeks.
Gene copy number remained similar for most CpGrich
clones and stayed above 80 % with only CpGrich-B10
exhibiting a drop to 26 % after the eight weeks (Fig. 4a).
Most of the CpGfree clones also maintained their gene
(See figure on previous page.)
Fig. 3 Comparing EGFP expressing level and stability of clones using the CpGrich and CpGfree promoters. a Mean fluorescence intensity (MFI) of
30 stably transfected clones for each promoter at week 0 before selection pressure was removed at the start of stability testing. Stability testing
was subsequently performed by culturing the cells in selection free media for 8 weeks. The clones were randomly isolated from three separately
generated pools. b Percentage of EGFP expressing cells after 8 weeks stability testing. c Retained EGFP expression after 8 weeks stability testing.
Each point represents the MFI of an individual clone and the horizontal bar represents the average MFI of the 30 clones. Values of CpGfree clones
which are statistically different from CpGrich are indicated by an *(p < 0.05)
Fig. 4 Comparing relative EGFP gene copies and mRNA levels. EGFP Gene copies were determined for (a) CpGrich and (b) CpGfree (b) clones
and relative EGFP mRNA levels for (c) CpGrich and (d) CpGfree clones at week 0 and week 8. β-actin and eukaryotic translation elongation
factor-1 alpha-1 (EF-1α) served as the internal controls to normalize the variation in input amount and quality of DNA and mRNA respectively.
Retained EGFP expression level, gene copy and mRNA values in the tables were calculated as the ratios of their values at the end of stability
testing at week 8 to their starting levels at week 0. Black bar represents values for week 0 and the grey bar represents week 8. Each point and
standard deviation represents the average derived from replicated measurements of two separately prepared samples
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copy numbers and only one clone, CpGfree-B4, dropped
to only 27 % of initial gene copies (Fig. 4b). There was
little correlation between the change in gene copies and
the retained EGFP expression levels for both promoters
(R2 = 0.355 for CpGrich and R2 = 0.152 for CpGfree). We
next looked at the mRNA levels before and after stability
testing for the same set of nine clones from each pro-
moter. mRNA levels generally correlated better to the
changes in EGFP expression levels. mRNA levels de-
creased to between 5 and 59 % of the starting levels at
week 0 after stability testing for the CpGrich clones
(Fig. 4c). CpGrich-B5 which retained the least expression
also retained the lowest mRNA level. mRNA levels for
some of the clones which maintained EGFP expression,
like clone CpGrich-C12, still decreased to 50 %. The
change in mRNA levels correlated better with the change
in EGFP expression levels as compared to the gene copy
data (R2 = 0.836). The only exception was CpGrich-B10
which had a larger than expected drop in mRNA levels to
only 6 % while maintaining 20 % expression, possibly due
to the large drop in the gene copy number described earl-
ier. Changes to the mRNA expression level for the
CpGfree clones also correlated better to the retained
EGFP expression (R2 = 0.737) (Fig. 4d). Clone CpGfree-B2
which retained 2.98 % EGFP expression also retained the
lowest mRNA level at 1.85 %. Both of the stable clones
CpGfree-C5 and -A11 which retained 94 % and 114 %
EGFP expression also retained the most mRNA levels of
78.9 % and 69.3 % (Fig. 4d).
Our attempts to improve expression stability for a re-
combinant protein using a CpGfree promoter did not
yield significant improvement. It was interesting that the
CpGfree promoter which had no CpG sites available for
DNA methylation did not perform much better than the
CpGrich promoter. We selected two unstable clones
which maintained gene copies (>80 %) but exhibited
both decreased mRNA levels and expression levels, and
one stable clone which maintained EGFP expression
level (>90 %) for further ChIP studies.
ChIP analysis of the clones before and after stability
testing
Clones B5, C4 for CpGrich and clones A1, B2 for the
CpGfree were selected as the unstable clones. The stable
clones selected for analysis were C12 and C5 for the
CpGrich and CpGfree promoters respectively. All of
the clones maintained their gene copies during stability
testing. ChIP was performed separately using four anti-
bodies anti-5-mC, anti-H3K9Ac, anti-H3K9Me3, and
anti-HP1 on both the week 0 and week 8 samples for the
selected clones. Methylated cytosines on CpG dinucleotides
which are common markers for unstable CHO cell lines
were first targeted using the anti-5-mC antibodies for pre-
cipitation. CpGrich clones B5 and C4 with EGFP retention
of only around 1 % was enriched by 8-fold and 4-fold re-
spectively when comparing their week 8 with week 0 sam-
ples (Fig. 5a). The stable CpGrich-C12 which maintained
expression above 100 % was instead depleted at week 8. No
enrichment was observed for all the three CpGfree clones
analyzed A1, B2 and C5, which was consistent with the ex-
pectation that the CpGfree promoter has no CpG sites for
methylation.
Analysis was next performed for the major histone
modification markers of histone H3 lysine9 (H3K9)
acetylation and trimethylation using the respective anti-
bodies for enrichment. Acetylated histones favor open
chromatin structures and correlate strongly with active
gene transcription [37]. H3K9 acetylation decreased to
below 0.1 for unstable clones of both the CpGrich and
CpGfree clones (Fig. 5b). There was an enrichment of
more than 2-fold for the stable CpGrich-C12 and no sig-
nificant changes to the stable CpGfree-C5 clone. H3K9
trimethylation is commonly associated with loss of re-
combinant gene expression [38] and this was reflected in
the unstable clones which had 2.5-fold to 6.2-fold en-
richment for week 8 samples as compared to samples
collected at the start of stability testing when using anti-
H3K9Me3 antibodies (Fig. 5c). The stable clone was also
enriched but at a lower level. Among the stable clones,
CpGrich-C12 had 2.2-fold enrichment and CpGfree-C5
had 1.4-fold enrichment. Heterochromatin protein 1 (HP1)
is a nucleosomal protein associated with gene repression
associated with position effect variegation [39, 40]. When
anti-HP1 antibody was used for enrichment, samples of
CpGrich-B5 and -C4 at week 8 exhibited enrichment of
3-fold and 6.6-fold higher than samples from week 0
(Fig. 5d). Stable CpGrich-C12 was lower at week 8 at
0.4-fold of week 0 levels. While the stable CpGfree
clone, C5, was also depleted at week 8 at about 0.5-fold,
the unstable CpGfree clones gave contrasting results.
CpGfee-A1 enriched using anti-HP1 was 0.4-fold of the
starting levels while CpGrich-B2 was 1.9-fold higher
than week 0.
Effect of chemical treatment on restoring EGFP
expression
Week 8 samples of the clones used for ChIP analysis
were treated with 5-Aza-dC, a DNMT inhibitor, and
NaBu, a HDAC inhibitor. The cells were treated for 24 h
before mean fluorescent intensity level of EGFP were an-
alyzed by FACS. Treating the unstable cells using 5-Aza-
dC did not result in any significant improvements in
EGFP expression (Fig. 6). Using NaBu had greater effect
and the EGFP levels for all the unstable clones improved
around 1.5-fold compared to the untreated samples. Both
the stable clones tested, CpGrich-C12 and CpGfree-C5,
did not exhibit any significant changes. These results indi-
cated that histone modifications play a more important
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role at silencing the gene expression during long term cul-
ture compared to DNA methylation.
Discussion
Methylated CpG dinucleotides are commonly associated
with loss of recombinant gene expression in CHO cell
lines [4, 6, 13]. In this study, we evaluated the use of the
promoter, CpGfree, which was devoid of CpG for re-
combinant protein production in CHO cells and com-
pared it with CpGrich, a promoter with similar structure
but contains CpG dinucleotides. Transient EGFP expres-
sion levels were similar but CpGrich had significantly
lower expression in stably transfected cell lines. After
8 weeks of culturing in the absence of selection pressure
for stability testing, CpGfree clones maintained a larger
proportion of cells still expressing the recombinant protein.
This greater proportion of protein expressing population
did not translate to an actual higher protein expression
level and we observed no significant difference in the
retained EGFP levels when comparing the week 8 levels to
the starting levels. The drop in gene expression was not a
result of losing gene copies for most clones but instead de-
creased transcription leading to lower mRNA levels for
both promoters. ChIP analysis revealed that the vector inte-
grated on the chromosome for unstable CpGrich clones
were enriched for 5-methylcytosine and H3K9 trimethyla-
tion, and depleted for H3K9 acetylation. The CpGfree
clones which lost the majority of their expression also ex-
hibited similar chromatin histone associations even without
any methylated sites on the promoter. Gene silencing due
to histone modifications appeared to reduce the benefits of
using CpGfree to improve long-term recombinant protein
Fig. 5 Comparing DNA methylation and histone modifications for unstable and stable clones for CpGfree and CpGrich promoters by ChIP assays.
DNA was extracted from samples of two unstable clones and one stable clone for each promoter and immunoprecipitation performed using four
different antibodies: (a) anti-5-mC, (b) anti-H3K9Ac, (c) anti-H3K9Me3 and (d) anti-HP1. Enrichment was measured by real-time quantitative PCR.
Black and grey bars represent data for samples from week 0 and from week 8 respectively. Results were normalized to their week 0 results and
each bar represents triplicate measurements of two separate sets of experiments
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expression stability in CHO cells. Histone modifications
were also identified as better indicators of expression stabil-
ity than CpG methylation and histone binding proteins like
HP1. Treatment of the unstable clones using a HDAC
inhibitor also yielded a more significant improvement
of recombinant EGFP expression compared to a DNMT
inhibitor. The DNMT inhibitor used, 5-Aza-dC, had been
previously reported to have limited effect at restoring gene
expression in CHO clones [13].
Transgenes have the potential to be silenced within
days of integrating into the chromosome in applications
involving CHO cells, stem cells and gene therapy in lung
cells [12, 33, 41]. The transfected genes can also be tar-
geted for repeat-induced gene silencing when a high
number of gene copies are integrated for recombinant
mammalian cell lines [12]. We had observed that the
transient EGFP expression levels of the two promoters
were similar but expression of stably transfected pools
and clones after drug selection for CpGfree was signifi-
cantly higher. The overall higher EGFP expression would
also mean higher expression of the selection marker as
the genes were linked by IRES and this was a possible
reason why CpGfree pools recovered faster during selec-
tion. We had also previously observed that including ex-
pression augmenting elements which reduce the effects
of gene silencing increased the number of colonies sur-
viving drug selection without increasing recombinant
gene expression [23]. The benefits of using CpGfree to
possibly reduce early silencing upon vector integration
include obtaining stable pools faster and being able to
use higher selection drug concentrations for a more
stringent selection process. While not determined in our
study, other reports had indicated that integrated trans-
genes remain unmethylated during early stages of trans-
fected CHO cell lines [13, 42, 43]. It is also possible that
the higher early expression when using the CpGfree pro-
moter could have arose due to differences in the factors
recruited or chromatin modifications compared to the
CpGrich promoter and future follow-up analysis could
provide some interesting results.
While CpG methylation is linked to gene silencing,
studies have indicated that methylation does not always
initiate silencing but is possibly a downstream event after
the gene gets silenced [20, 43]. We had expected that the
CpGfree promoter to confer some benefits for sustained
recombinant protein expression even if methylation was
only a partial reason for loss of gene expression. Our stud-
ies yielded no significant benefits to long-term stable ex-
pression when using the CpGfree promoter as the EGFP
expression retained was similar to the CpGrich promoter.
Majority of the clones analyzed for both promoters did
not lose gene copies but exhibited a drop in mRNA level,
a phenomenon which had been reported by other studies
as well [3, 44]. Any loss of gene copies could have arose
during homologous recombination to repair DNA strand
breaks [45]. Some clones maintained EGFP levels despite
a drop in mRNA levels were possibly limited by transla-
tion rate or saturation of the intracellular protein levels.
Fig. 6 Restoring EGFP expression using DNA methyltransferase (DNMT) inhibitor, 5-Aza-2′-deoxycitidine (5-Aza-dC), and histone deacetylase (HDAC)
inhibitor, sodium butyrate (NaBu). Clones generated using CpGrich (B5, C4 unstable clones and C12 stable clone) and CpGfree (A1,B2 unstable clones
and C5 stable clone) at week 8, the end of stability testing, were treated with DNMT or HDAC inhibitors for 24 h before MFI was measured again. Black
bars represent samples without treatment, grey bars for samples treated with 5-Aza-dC and white bars represent samples treated with NaBu.
Each bar represents duplicate measurements of two independent experiments for each clone. MFI values were normalized to the untreated control
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The CpGfree clones appeared to be more resistant to total
silencing of the gene as seen by the larger proportion of
the population still expressed detectable levels of EGFP.
High density DNA methylation is required for stable epi-
genetic imprint for transfer of transcriptional repression
[46]. Using CpGfree could have impeded the complete
and stable silencing of transgenes, allowing cells to express
EGFP for longer periods.
Both ChIP data and chemical inhibitor treatment of
selected unstable clones linked the decreasing gene
expression of the CpGfree promoter to chromatin
modifications of increased H3K9 trimethylation and
deacetylation. It had been shown that histone H3
hypoacetylation is linked to loss of recombinant gene
expression using simian virus 40 (SV40) promoter driven
vectors in CHO cells [47]. Another study performed using
a CMV promoter to drive gene expression in CHO cells
also observed that histone modifications were playing a
role in regulating transgene expression during clone gen-
eration [42]. Similar loss of gene expression had been ob-
served with a range of promoters in CHO cells, indicating
that promoter choice which is commonly associated with
expression stability might not be as important as we ex-
pected. Another interesting observation made was the
depleted HP1 for the unstable CpGrich clone A1. There
are reports of competitive binding by other proteins
like DNMT3a displacing HP1 and could be the reason
for lower HP1 in some samples [48]. The interactions
and processes related to histone modifications still re-
quire more work to obtain a better understanding [38]
and until then, proteins interacting with histone modi-
fications might not be good indicators for expression
stability. Screening of the promoters using TRANSFAC®
software identified binding sites for factors like YY1 which
can down-regulate gene expression and could be another
possible reason for the failure of CpGfree at improving
long-term stability [49, 50].
Conclusion and future work
Long-term expression stability is arguably of greater
importance to large scale production of protein thera-
peutics than many other applications of recombinant
protein expression in mammalian cells due to the health
and commercial implications. While the CpGfree promoter
devoid of DNA methylation sites did not improve the per-
centage of expression retained, it could possibly still be use-
ful during the early stages of generating recombinant CHO
cell lines with its potential resistance to early gene silencing.
The faster recovery during selection would help shorten
the timeline required to generate stable pools. The higher
initial titer from these stable pools would allow fast
generation of more material using stably transfected
pools for early assay development and laboratory testing.
Our observation that a significantly larger proportion of
cells were still producing the recombinant protein after
prolonged passaging with the CpGfree promoter is not as
that critical to therapeutics production where the main
concern is the collective productivity level. It could still be
important to cell engineering studies where high expres-
sion level is not as critical.
We observed that preventing CpG methylation alone
does not prevent gradual gene silencing as histone modi-
fications which repress recombinant gene expression still
take place. Further analysis of histone modifications to
identify other possible correlations could also aid in pro-
viding a clearer picture of the interactions which affect
long-term gene expression in CHO cells. There had been
attempts to identify recombinant CHO cell lines with
long-term stable protein production using markers like
DNA methylation hotspots on the promoter [4]. Based
on our observations, histone modification markers might
be better indicators of expression stability and also targets
for engineering to improve long-term expression stability.
Our results could be promoter specific and the stability
of other promoters could still benefit from removal of
CpG dinucleotides. Our experience with removing CpGs
from commonly used promoters with random mutations
mostly yielded promoters with lower strengths. A system-
atic method to remove CpG dinucleotides without impair-
ing the strength of the promoter would be required for
more promoters and their CpG free versions need to be
compared. Another area which could provide some im-
provements to expression stability is codon optimization.
Current codon optimization for recombinant protein ex-
pression in CHO cells are focused more on expression
level and not for sustained gene expression [51, 52].
Analysis of the protein sequences which are expressed
at constant levels throughout long-term passaging of
CHO cultures could provide some information on de-
signing silencing-proof promoters and gene sequences.
Follow up studies using site-specific integration and
lentiviral transfection could provide added insights to
the effects of integration site and copy number on using
CpGfree promoters in CHO cells.
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